“…However, a high risk of progressive tissue ingrowth or overgrowth through the stent meshes has been reported, and these situations are still considered significant obstacles to successful stent placement (Wadhwa et al, 2003;Kim et al, 2014;Jeong, 2016). To treat tissue hyperplasia or tumor growth adjacent to the implanted SEMS in non-vascular luminal organs, various functionalized stents with the use of antiproliferative or anticancer drugs, small interfering RNA, nanomaterials, and shape modifications have been developed and investigated (Lee et al, 2009;Van Hooft et al, 2011;Kim et al, 2014;Park et al, 2014;Jun et al, 2017;Jeon et al, 2022;Park et al, 2022). However, it remains an unresolved problem in the clinic, and a standard therapeutic strategy has not been established (Park et al, 2019).…”